Finally, given the popularity of cisplatin in treating a wide range of cancers, we expect that cisplatin treatment in combination with LNA inhibitors or BCKDK inhibitors could help minimize the occurrence of unwanted nephrotoxicity incidental to cisplatin while decreasing tumor mass. Here, BCKDK is linked to neoplasm.